Michael O'Reilly, MD, Masimo Executive Vice President of Medical Affairs, stated; "The 13 new studies presented at ASA this year add to the growing body of evidence showing that the use of Masimo SET pulse oximetry and Masimo Rainbow SET Pulse CO-Oximetry improves patient safety and outcomes."
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that
significantly improve patient care -- helping solve "unsolvable" problems.
In 1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse
oximetry, known as Masimo SET, which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides
the most reliable SpO2 and pulse rate measurements even under the most
challenging clinical conditions, including patient motion and low
peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive
|SOURCE Masimo Corporation|
Copyright©2008 PR Newswire.
All rights reserved